ArticleJournal of orthopaedic surgery and research2025
Neuregulin 4 inhibits synovial macrophage pro-inflammatory polarization via ErbB4/Stat5b/NF-κB signaling to alleviate osteoarthritis progression.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Synovial macrophage rhoa protects against osteoarthritis by suppressing YAP/IL-17C mediated chondrocyte senescence.Cell biology and toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Osteoarthritis (OA) is a chronic inflammatory disease characterized by synovial inflammation and cartilage degradation. Synovial macrophages, as a key driver of OA progression, during all stages of OA and induced to produce inflammatory cytokines that aggravate the degradation of cartilage. Here, we demonstrate that neuregulin-4 (Nrg4) deficiency exacerbates synovial pro-inflammatory macrophage transformation and articular cartilage abrasion in a mouse model of OA. Conversely, Nrg4 re-expression significantly reduces pro-inflammatory macrophage accumulation and synovial inflammation, thereby attenuating OA progression. Mechanistically, Nrg4 activates the ErbB4/Stat5b signaling pathway, which subsequently suppresses NF-κB activation, leading to reduced pro-inflammatory macrophage transformation and pro-inflammatory cytokine production. In vitro experiments further confirm that Nrg4 directly inhibits macrophage infiltration. These findings reveal a novel role for Nrg4 in modulating synovial macrophage transformation through the ErbB4/Stat5b/NF-κB axis, offering a potential therapeutic strategy for OA by targeting synovial inflammation. This study also expands our understanding of OA protection beyond chondrocyte protection, emphasizing its role in regulating the synovial microenvironment and cartilage homeostasis in OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.